Home > Compound List > Product Information
3-Indoleacetonitrile_Molecular_structure_CAS_771-51-7)
Click picture or here to close

3-Indoleacetonitrile

Catalog No. 129453 Name Sigma Aldrich
CAS Number 771-51-7 Website http://www.sigmaaldrich.com
M. F. C10H8N2 Telephone 1-800-521-8956
M. W. 156.18392 Fax
Purity 98% Email
Storage Chembase ID: 74538

SYNONYMS

Title
3-吲哚乙腈
IUPAC name
2-(1H-indol-3-yl)acetonitrile
IUPAC Traditional name
indole-3-acetonitrile
Synonyms
IAN
Indolylacetonitrile
3-(Cyanomethyl)indole
(3-Indolyl)acetonitrile
NSC 523272
吲哚-3-乙腈

DATABASE IDS

Beilstein Number 125488
PubChem SID 24847904
CAS Number 771-51-7
MDL Number MFCD00005628
EC Number 212-232-1

PROPERTIES

Empirical Formula (Hill Notation) C10H8N2
Purity 98%
Boiling Point 157-160 °C/0.2 mmHg(lit.)
Flash Point 112 °C
Flash Point 233.6 °F
Melting Point 33-36 °C(lit.)
GHS Pictograms GHS07
GHS Signal Word Warning
GHS Hazard statements H302-H312-H332
European Hazard Symbols Harmful Harmful (Xn)
MSDS Link Download
Personal Protective Equipment dust mask type N95 (US), Eyeshields, Gloves
GHS Precautionary statements P280
Risk Statements 20/21/22
RTECS AM0700000
Safety Statements 36/37
German water hazard class 3

DETAILS

Description (English)
Packaging
5, 25 g in glass bottle
Application
Reactant for preparation of:
• Tryptophan dioxygenase inhibitors pyridyl-ethenyl-indoles as potential anticancer immunomodulators1
• Histone deacetylase inhibitors2
• Potential kinase inhibitors3
• Kv7/KCNQ potassium channel activators4
• Kinesin-Specific MKLP-2 Inhibitor5
• Pesticides6
• Potential PET cancer imaging agents7
• Agonists of the Farnesoid X Receptor (FXR) as atherosclerosis treatment8
• Butyrylcholinesterase inhibitors9
• Necroptosis inhibitors10
Description (简体中文)
包装
5, 25 g in glass bottle
Application
Reactant for preparation of:
• Tryptophan dioxygenase inhibitors pyridyl-ethenyl-indoles as potential anticancer immunomodulators1
• Histone deacetylase inhibitors2
• Potential kinase inhibitors3
• Kv7/KCNQ potassium channel activators4
• Kinesin-Specific MKLP-2 Inhibitor5
• Pesticides6
• Potential PET cancer imaging agents7
• Agonists of the Farnesoid X Receptor (FXR) as atherosclerosis treatment8
• Butyrylcholinesterase inhibitors9
• Necroptosis inhibitors10

REFERENCES